Latest Singapore News

SenSen Networks has opened FY27 with record quarterly customer cash receipts of A$5.3 million, 17% annualised recurring revenue growth and positive operating cash flow. The ASX-listed AI enforcement software company also secured A$2.6 million in new and expansion contracts, although converting those wins into recurring revenue remains the next test.

BPH Energy’s latest quarter puts its portfolio risks in sharp relief: Advent is appealing the PEP11 ruling while another subsidiary remains in voluntary administration. BPH ended September with $1.127 million in cash, but deployed $972,000 in loans to investees during the quarter.

Love Group’s customer cash receipts fell to A$626,000 in the first quarter of FY27, with management blaming a sharp drop in Google Ads return on spend. The company ended September with A$2.014 million in cash and an estimated eight quarters of funding at the latest burn rate.

Cynata Therapeutics has opened a fully underwritten $913,000 entitlement offer to fund adviser, director and consultant fees, offer costs and working capital. Eligible shareholders can buy three new shares for every eight held, with free options attached.

Firebrick Pharma has secured Philippine marketing approval for Nasodine Nasal Spray as an over-the-counter antiseptic, opening a potential launch in the 116 million-person market from early 2027. The approval remains subject to post-approval documentation and future revalidation.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.

Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.

De.mem has reported its strongest quarterly operating cash flow on record, with September cash receipts rising 29% year on year to approximately $10.1 million. The water treatment company also secured an $800,000 antiscalant framework agreement and two equipment orders due for delivery in 2027.

Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.

TZ Limited is still seeking funding after failing to complete its shortfall share placement, with $1.3 million in debt and vendor obligations due. The company says a management restructure, cost cuts and commercial opportunities could improve cash generation, but several forecasts remain conditional.

Guzman y Gomez delivered 18.8% network sales growth in Q1 FY27, with comparable sales up 7.1% as its Australian restaurant base expanded. The company also reaffirmed its earnings and expansion targets while approving a further buyback extension of up to $100 million.